Caris Life Sciences (CAI) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $6.62B
- As of Nov 13, 2026
- P/E
- Not available
- Trailing twelve months
- P/B
- 10.35x
- Latest reported equity
- P/S
- 6.94x
- Trailing twelve months
- ROE
- -0.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $6.62B
- As of Nov 13, 2026
- P/E
- Not available
- Trailing twelve months
- P/B
- 10.35x
- Latest reported equity
- P/S
- 6.94x
- Trailing twelve months
- ROE
- -0.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
—
P/B
10.35x
P/S
6.94x
Earnings and dividend metrics▾
Earnings
EPS
-$0.02
Earnings per share
BPS
$2.23
Book value per share
ROE
-0.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.02 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $2.23 of net assets.
- ROE — shareholder equity shrank by 0.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 26.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $217M+26.7%
—
FY24 Q3
$217M
Jul–Sep '25
$275M
Jul–Sep '26
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share decreased 37.5% from the same quarter a year earlier.
- Revenue increased 26.7% from the same quarter a year earlier.
- Operating income decreased 42.4% from the same quarter a year earlier.
- Net income decreased 37.5% from the same quarter a year earlier.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Denton John RusselSee Remarks · Sep 22, 2026Open-market sale7,500 shares · $239KAvg. price $31.8168174,855 shares held after
- Brille Brian JSee Remarks · Sep 17, 2026Open-market sale400,000 shares · $12.1MAvg. price $30.3302230,303 shares held after
- Brille Brian JSee Remarks · Sep 17, 2026Option exercise400,000 shares · $976KAvg. price $2.44630,303 shares held after
- Spetzler David BaxleyPresident · Sep 4, 2026Open-market sale119,212 shares · $3.0MAvg. price $24.75521,182,871 shares held after
- Spetzler David BaxleyPresident · Sep 4, 2026Option exercise250,000 shares · $610KAvg. price $2.441,302,083 shares held after
- Spetzler David BaxleyPresident · Sep 3, 2026Open-market sale478,000 shares · $11.9MAvg. price $24.8598
Show 2 price lots
- 393,100 shares × $24.7604$9.7M
- 84,900 shares × $25.3201$2.1M
- Spetzler David BaxleyPresident · Sep 3, 2026Option exercise1,000,000 shares · $2.4MAvg. price $2.441,530,083 shares held after
- Vacirca Jeff LDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $062,863 shares held after
- JOHANSEN LAURA IDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $0343,897 shares held after
- Fredrickson David PaulDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $031,813 shares held after
- HALBERT JONDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $0131,813 shares held after
- Minor LloydDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $031,813 shares held after
- CASTLEMAN PETER MDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $029,321 shares held after
- Gilliam Joseph EDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $029,321 shares held after
- PHILLIPS T DANNYDirector · Aug 14, 2026Grant or award13,192 shares · $0Avg. price $0133,060 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Caris Life Sciences (CAI) stock information
NASDAQ
Caris Life Sciences (CAI) is listed on NASDAQ. Its market capitalization is about $6.6B. Return on equity is -0.9%. These figures are computed in-house from official filings and are reference information only.
Caris Life Sciences — frequently asked questions
- What is the market capitalization of Caris Life Sciences?
- CAI has a market capitalization of about $6.6B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.